- Home
- NBIX
as 08-29-2025 4:00pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 13.2B | IPO Year: | 1996 |
| Target Price: | $160.94 | AVG Volume (30 days): | 782.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.39 | EPS Growth: | 2.97 |
| 52 Week Low/High: | $84.23 - $154.61 | Next Earning Date: | 10-29-2025 |
| Revenue: | $2,509,900,000 | Revenue Growth: | 18.42% |
| Revenue Growth (this year): | 20.66% | Revenue Growth (next year): | 14.64% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | N/A | Aug 7 '25 | Sell | $126.41 | 106,322 | $13,440,280.97 | 514,596 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
High Growth Tech Stocks To Watch In The US August 2025
Zacks
9 days ago
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Zacks
17 days ago
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Simply Wall St.
a month ago
High Growth Tech Stocks In US To Watch July 2025
Zacks
a month ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
MT Newswires
a month ago
Truist Securities Initiates Coverage on Neurocrine Biosciences With Buy Rating, $163 Price Target
PR Newswire
2 months ago
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Argus Research
2 months ago
NBIX: Raising target price to $135.00
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.